846033-37-2

Basic information

• Product Name: 7-FLUORO-[1,8]NAPHTHYRIDIN-2-OL
• Synonyms: 7-Fluoro-[1,8]naphthyridin-2-ol ,96%;2-Fluoro-7-hydroxy-1,8-naphthyridine;1,8-Naphthyridin-2(1H)-one, 7-fluoro-;7-fluoro-1H-1,8-naphthyridin-2-one
• CAS NO: 846033-37-2
• Molecular Formula: C₈H₅FN₂O
• Molecular Weight: 164.14
• Product Categories: Building Blocks;Chemical Synthesis;Fluorinated Building Blocks;Heterocyclic Fluorinated Building Blocks;Other Fluorinated Heterocycles;Others
• Mol File: 846033-37-2.mol
• Article Data: 3

Chemical Properties

• Melting Point: 280-281°C
• Boiling Point: 376.1 °C at 760 mmHg
• Flash Point: 181.3 °C
• Appearance: /
• Density: 1.373 g/cm³
• Vapor Pressure: 7.4E-06mmHg at 25°C
• Refractive Index: 1.576
• CAS DataBase Reference: 7-FLUORO-[1,8]NAPHTHYRIDIN-2-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 7-FLUORO-[1,8]NAPHTHYRIDIN-2-OL(846033-37-2)
• EPA Substance Registry System: 7-FLUORO-[1,8]NAPHTHYRIDIN-2-OL(846033-37-2)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-37/38-41
• Safety Statements: 26-39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 846033-37-2(Hazardous Substances Data)

Usage

Chemical Properties

yellow solid

InChI:InChI=1/C8H5FN2O/c9-6-3-1-5-2-4-7(12)11-8(5)10-6/h1-4H,(H,10,11,12)

Upstream product

• 632620-24-7 7-Amino-1H-[1,8]naphthyridin-2-one sulfate 
• 141-86-6 2.6-diaminopyridine 
• 1931-44-8 2-amino-8H-7-oxo-[1,8]-naphthyridine 

Downstream Products

• 846031-29-6 C₂₃H₂₉ClN₄O₂ 
• 846031-35-4 C₂₃H₂₆ClF₃N₄O₂ 
• 1309857-71-3 C₂₃H₂₆ClF₃N₄O₂ 

Relevant articles and documents

Efficient syntheses of dual radioisotope-labelled PF-00217830, a D 2-partial agonist for the treatment of schizophrenia disorder

PF-00217830 is a D2-partial agonist developed for the treatment of schizophrenia. The dual 14C/14C and 14C/3H-labelled PF-00217830 were required for animal and human absorption, distribution, metabolism and elimination (ADME) studies. This report describes the development of the syntheses of dual 14C/ 14C- and dual 14C/3H-labelled PF-00217830. [14C]PF-00217830-L labelled at the naphthalene ring was prepared in three steps starting with [14C]naphthalene, while [ 3H]PF-00217830-R was synthesised by Pd-catalysed tritium de-bromination of brominated PF-00217830 in a single radiosynthetic step. The dual [14C/3H]PF-00217830 was made by mixing 1:10 radioactivity ratio of [14C]PF-00217830-L and [3H]PF- 00217830-R. The chemistry for [14C]PF-00217830-R labelled at the pyridine ring was also described.

7-(4-(4-[3-CHLORO-2-(TRIFLUOROMETHYL)PHENYL]PIPERAZIN-1-YL)BUTOXY)-[1,8]-NAPHTHYRIDIN-2(1H)-ONE

This invention relates to a compound of formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the compound or a salt thereof, and its use as a medicament for the treatment of schizophrenia, bipolar disorder, or other central nervous system disorders.